Ottawa, ON / TNW-Accesswire / May 25, 2018 / – Avivagen Inc. (TSXV:VIV)(“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, announces that it has retained Meyenberg International Group (MIG) as its agent to help Avivagen pursue regulatory approval for the use of Avivagen’s OxC-beta™ in livestock in Mexico. Meyenberg anticipates that the regulatory process should require approximately one year following of the signing of this agreement.

MIG will perform a strategic analysis of regulatory authorization routes within the Mexican jurisdiction, in order for Avivagen to offer its OxC-beta™ range of products for use in livestock in Mexico.  MIG will be coordinating and developing dialogue with the Mexican regulatory governmental bodies as well as preparing registration dossiers and stewarding through regulatory and laboratory assessments in connection with seeking registration in Mexico.

Once the analysis is done, MIG will provide Avivagen with categories in which the product could be registered and requirements, along with a strategic plan on how to best achieve an effective commercialization and distribution of its product once registration is completed.

“As we continually emphasize, a primary focus of our company is to expedite the regulatory process and approvals in new jurisdictions, which in turn will open us up to increased sales,” stated Mr. Kym Anthony, Chairman & Interim CEO.  “With annual feed consumption of 35 million metric tons of feed, Mexico represents a tremendous opportunity for Avivagen and our agreement with MIG will enable us to move closer to accessing this important market. We will provide updates with respect to other country regulatory process in the near-term.”

About Avivagen

Avivagen Inc. is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com.

About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology arises from Avivagen’s discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors. Specifically, Avivagen has discovered the naturally occurring compound that is the actual source of β-carotene’s non-vitamin A activity and uses the synthetic version of the compound as the source of activity of Avivagen’s OxC-beta™ products. Importantly, the OxC-beta™ compound is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand.

About Vivamune™ Health Chews (Vivamune)

Vivamune is an all-in-one chew that can dramatically simplify a pet’s supplement routine. Featuring a newly-discovered, novel immune-supporting active ingredient, OxC-beta™, Vivamune targets joints, skin and digestive health all in a single, tasty chew a pet will love. Vivamune is available for sale in the United States. For more information, visit www.vivamunehealth.com.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements regarding the process and timing for seeking regulatory approvals, the possibility of receiving such approvals, the activities of MIG and the possible outcomes of those activities and the possibility for registration in Mexico to increase Avivagen Inc.’s sales are forward looking statements.  Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen may not gain market acceptance or regulatory approval in Mexico in the time frame anticipated or at all and, if regulatory approval is granted, it may not have the anticipated effects on Avivagen Inc.’s sales due to many factors, many of which are outside of Avivagen’s control.   Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733
E-mail: d.basek@avivagen.com

Kym Anthony
Chairman & Interim CEO
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com